Contineum Therapeutics Inc.
CTNM | NASDAQ
$13.59
+$0.04 (+0.30%)
Sep 22, 2026, 12:11 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 50M | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | 79K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 42K | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | -79K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 49.96M | n/a | n/a |
Operating Income | -17.43M | -16.9M | -17.12M | -14.93M | -17.9M | -18.11M | 84.74M | -12.97M | -10.94M | -9.93M | -9.68M | -8.07M | 38.94M | -5.12M | -5.45M |
Interest Income | 2.34M | 2.51M | 2.01M | 1.96M | 2.03M | 2.25M | 2.53M | 2.74M | 2M | 1.64M | 1.79M | 1.74M | 679K | 401K | 342K |
Pretax Income | -15.15M | -14.46M | -15.16M | -12.79M | -16.04M | -15.99M | -14.57M | -10.27M | -9.01M | -8.42M | -7.93M | -6.37M | 42.29M | -4.82M | -7.51M |
Net Income | -15.15M | -14.46M | -15.16M | -12.79M | -16.04M | -15.99M | -14.57M | -10.27M | -9.01M | -8.42M | -7.77M | -6.25M | 41.56M | -4.82M | -7.51M |
Selling & General & Admin | 4.73M | 5.26M | 4.36M | 3.94M | 3.84M | 4.4M | 4.03M | 3.25M | 3.04M | 2.15M | 1.66M | 1.57M | 1.6M | 1.48M | 1.5M |
Research & Development | 12.7M | 11.65M | 12.76M | 10.99M | 13.98M | 13.71M | 13.02M | 9.73M | 7.9M | 7.78M | 8.01M | 6.5M | 9.46M | 3.63M | 3.95M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | -101.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 17.43M | 16.9M | 17.12M | 14.93M | 17.82M | 18.11M | -84.74M | 12.97M | 10.94M | 9.93M | 9.68M | 8.07M | 11.06M | 5.12M | 5.45M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 116K | 92K | 101K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 16.9M | 17.12M | 14.93M | 17.9M | 18.11M | -84.74M | 12.97M | 10.94M | 9.93M | 9.68M | 8.07M | 11.06M | 5.12M | 5.45M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -161K | -118K | 729K | n/a | n/a |
Shares Outstanding (Basic) | 37.47M | 37.34M | 30.86M | 28.12M | 25.9M | 25.87M | 25.85M | 25.74M | 25.72M | 25.72M | 25.13M | 25.13M | 25.72M | 25.72M | 25.13M |
Shares Outstanding (Diluted) | 37.47M | 37.34M | 30.86M | 28.12M | 25.9M | 25.87M | 25.85M | 25.74M | 25.72M | 25.72M | 25.13M | 25.13M | 25.72M | 25.72M | 25.13M |
EPS (Basic) | -0.40 | -0.39 | -0.49 | -0.45 | -0.62 | -0.62 | -0.56 | -0.40 | -0.35 | -0.33 | -0.05 | -0.25 | 1.62 | -0.19 | -0.30 |
EPS (Diluted) | -0.40 | -0.39 | -0.49 | -0.45 | -0.62 | -0.62 | -0.56 | -0.40 | -0.35 | -0.33 | -0.05 | -0.25 | 1.62 | -0.19 | -0.30 |
EBITDA | -17.43M | -14.37M | -15.07M | -12.71M | -15.96M | -15.91M | -14.49M | -10.21M | -8.95M | -8.36M | -7.89M | -6.33M | 42.45M | -4.66M | -7.33M |
EBIT | n/a | -14.46M | -15.16M | -12.79M | -16.04M | -15.99M | -14.57M | -10.27M | -9.01M | -8.42M | -7.93M | -6.37M | 42.41M | -4.73M | -7.41M |
Depreciation & Amortization | n/a | 83K | 85K | 81K | 79K | 78K | 75K | 62K | 60K | 61K | 37K | 43K | 42K | 73K | 81K |
Add to Watchlist
Select watchlists to add or remove CTNM